Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sellas Life Sciences Group Inc SLS

Healthcare Biotechnology
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor... see more

Recent & Breaking News (NDAQ:SLS)

SELLAS Life Sciences Expands Executive Team with Appointment of Robert Francomano as Chief Commercial Officer

GlobeNewswire March 14, 2022

SELLAS Life Sciences Announces Final Court Approval of Settlement of Securities Litigation

GlobeNewswire February 28, 2022

SELLAS Life Sciences Announces Completion of Enrollment of Phase 1/2 Clinical Trial of GPS in Combination with Pembrolizumab in Advanced Metastatic Ovarian Cancer

GlobeNewswire February 1, 2022

SELLAS Life Sciences Announces IND Acceptance for First Clinical Trial of GPS in China

GlobeNewswire January 26, 2022

SELLAS Life Sciences Promotes John Burns to Senior Vice President, Finance and Chief Accounting Officer

GlobeNewswire January 5, 2022

SELLAS Life Sciences Announces Final Court Approval of Settlement of Derivative Litigation

GlobeNewswire November 23, 2021

SELLAS Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire November 12, 2021

SELLAS Life Sciences to Participate in Upcoming Conferences in October 2021

GlobeNewswire October 7, 2021

SELLAS Life Sciences Announces Settlement of Derivative Litigation

GlobeNewswire September 23, 2021

SELLAS Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 28th

GlobeNewswire September 14, 2021

SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire August 12, 2021

SELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on August 17, 2021

GlobeNewswire July 28, 2021

SELLAS Reports Promising Updated Clinical Data and Initial Immune Response Profiles from Ongoing Phase 1/2 Study of Galinpepimut-S (GPS) Combined with Keytruda for Treating WT1+ Advanced Ovarian Cancer

GlobeNewswire June 30, 2021

SELLAS Reports Encouraging Updated Clinical Data from Ongoing Mesothelioma Study of Galinpepimut-S (GPS) Combined with Opdivo

GlobeNewswire June 24, 2021

SELLAS Life Sciences Announces Inclusion in Russell Microcap® Index

GlobeNewswire June 22, 2021

SELLAS Life Sciences Announces USPTO Decision to Grant New Patent for Galinpepimut-S in Combination with Checkpoint Inhibitor Therapies

GlobeNewswire May 27, 2021

SELLAS Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire May 13, 2021

SELLAS Life Sciences to Host Shareholder Update Call on June 3rd

GlobeNewswire May 11, 2021

SELLAS Life Sciences Reports Full Year 2020 Financial Results and Provides Business Update

GlobeNewswire March 23, 2021

SELLAS Life Sciences to Participate in the M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference on March 17th

GlobeNewswire March 11, 2021